Untitled Document
  About prIME Oncology Cases in Multiple Myeloma
 
prIME Oncology Cases in Multiple Myeloma is a CME-certified series of 5 case studies, each with an expert perspective from internationally renowned thought leaders in multiple myeloma. Vote your preferred therapy choice(s) and immediately be able to view the aggregate, real-time results of their peers’ choices.
 
CASE 5: Induction Therapy for Multiple Myeloma in the Standard-Risk “Young” Patient

CASE 5: Induction Therapy for Multiple Myeloma in the Standard-Risk “Young” Patient

This brief case discussion examines the induction therapy options available for treating standard-risk “young” patients with multiple myeloma.

Discussant:
Sundar Jagannath, MD
St Vincent’s Comprehensive Cancer Center
New York, New York, United States
CASE 4: Relapsed Multiple Myeloma

CASE 4: Relapsed Multiple Myeloma

This brief case discussion examines therapy options available for treating patients with relapsed multiple myeloma.

Discussant:
Robert Z. Orlowski, MD, PhD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas, United States
CASE 3: Induction Therapy for Multiple Myeloma in the Elderly Patient

CASE 3: Induction Therapy for Multiple Myeloma in the Elderly Patient

This brief case discussion concerns a 74-year-old female with a history of coronary artery disease, chronic obstructive pulmonary disease, and peripheral vascular disease.

Discussant:
Antonio Palumbo, MD
University of Torino
Torino, Italy
CASE 2: Maintenance Therapy Post Autologous Stem Cell Transplantation

CASE 2: Maintenance Therapy Post Autologous Stem Cell Transplantation

This brief case discussion examines maintenance therapy post autologous stem cell transplantation.

Discussant:
William Bensinger, MD
Fred Hutchinson Research Center
Seattle, Washington, United States
CASE 1: Overcoming Adverse Risk Factors in the High-Risk “Young” Myeloma Patient

CASE 1: Overcoming Adverse Risk Factors in the High-Risk “Young” Myeloma Patient

This brief case discussion examines strategies for overcoming adverse risk factors leading to poor prognosis in high-risk “young” patients with multiple myeloma.

Discussant:

Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia, United States

RELATED ACTIVITY


MULTIPLE MYELOMA
 
prIME Oncology’s CommunityOpinion is a unique educational forum that engages oncologists by having clinical experts ask prIME Oncology network members their opinion on specific contemporary and controversial topics in oncology.

The CommunityOpinion forum allows participants to respond to, share, and view other members’ answers, as well as pose questions of their own.



Join the conversation. 
Join the conversation on multiple myeloma